GC Green Cross Signs Plasma Toll Manufacturing Agreement in Malaysia

Supply of Finished Products Such as Albumin and Immunoglobulin
Using Malaysian Plasma

Euncheol Heo, CEO of GC Green Cross (left), and Datuk Mohamed Nizam Bin Mohamed Jakel, CEO of SISB, are posing for a commemorative photo after signing a toll manufacturing agreement for plasma fractionation product supply. Photo by GC Green Cross

GC Green Cross announced on June 2 that it has signed a toll manufacturing agreement with 'Solid Intellectual SDN BHD (SISB)', a subsidiary of Malaysia's JAKEL Group, for the supply of plasma fractionation products.

The JAKEL Group is a leading private company in Malaysia, operating a diverse range of businesses. Within the group, SISB is the affiliate responsible for the distribution of pharmaceuticals and medical devices.

This agreement was finalized after GC Green Cross and SISB jointly participated in a plasma toll manufacturing project bid organized by Malaysian health authorities in March this year. This marks the first time that an Asian company, GC Green Cross, has been selected as the sole contractor for the entire project.

Under the terms of the agreement, Malaysian health authorities will supply plasma secured through the National Blood Center to SISB, which will then distribute the plasma to GC Green Cross. GC Green Cross will use this plasma as raw material to produce finished blood products such as albumin and immunoglobulin, which will then be exported back to SISB.

The company stated that it plans to supply blood products worth at least 24 million dollars (approximately 32.9 billion KRW) to Malaysia over a minimum period of four years starting in 2026.

Notably, this contract represents a new win for GC Green Cross, taking over a business that had been exclusively handled by the global pharmaceutical company CSL for about 15 years. This is the first time an Asian company has been selected as the contractor for this project.

Although Malaysia has not yet established a self-sufficient system for plasma fractionation products, the country is considered a promising market due to government-level efforts to strengthen infrastructure and policy support for stable product supply.

Lee Woojin, Head of the Global Business Division at GC Green Cross, stated, "We will continue to strengthen our position in the global plasma fractionation market through strategic partnerships between countries."